At NodeAI, we are revolutionizing lung cancer care by leveraging cutting-edge artificial intelligence to augment the accuracy and efficiency of endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA). Founded in 2023 by world-renowned thoracic surgeon Dr. Waël Hanna, in collaboration with leading AI experts , our mission is to democratize high-quality lung cancer staging and improve patient outcomes worldwide.

Lung cancer is the leading cause of cancer-related deaths globally, and accurate staging is critical for effective treatment planning. Unfortunately, 40% of EBUS-TBNA procedures result in inconclusive findings due to operator variability and the complexity of the procedure. NodeAI is addressing this challenge by offering a real-time AI adjunct  that provides guidance during EBUS procedures, enhancing operator precision, improving staging accuracy, and reducing the need for repeat biopsies.

Our cloud-based platform  integrates into existing clinical workflows, offering real-time AI analysis of ultrasound images and automated report generation. Our proprietary technology enhances lymph node detection, station identification, and malignancy prediction, enabling less experienced operators to achieve expert-level performance.

Lung cancer treatment relies on accurate staging to determine whether the cancer has spread to the lymph nodes. EBUS-TBNA is the gold standard for mediastinal lymph node staging, but it is a complex and expertise-dependent procedure. The high rate of inconclusive results due to operator variability often leads to treatment delays, unnecessary repeat procedures, and increased healthcare costs. NodeAI eliminates these barriers by providing AI-driven procedural support that standardizes the diagnostic process and improves patient outcomes.

The global lung cancer diagnostics market is projected to reach $6.6 billion by 2030, driven by the increasing demand for precision medicine and early detection technologies. EBUS-TBNA procedures are performed over 270,000 times annually across North America alone, presenting a significant opportunity for AI-enabled solutions like NodeAI. With no direct competitors currently offering real-time malignancy prediction for EBUS procedures, our first-mover advantage positions us to capture a significant share of this expanding market.

Our business model includes licensing agreements with major EBUS technology providers and a subscription-as-a-service offering that enables healthcare institutions to seamlessly adopt and benefit from our technology without significant upfront costs.

NodeAI's key differentiator lies in its unique combination of AI technology, clinical expertise, and comprehensive data collection. Unlike existing solutions that focus on post-procedure analysis, NodeAI provides real-time insights during the biopsy procedure itself. Our advantages include:

• Data Superiority: The world's largest and most diverse EBUS video dataset ensures unparalleled accuracy.
• Clinical Expertise: Developed in collaboration with leading thoracic surgeons and AI specialists.
• Seamless Workflow Integration: Vendor-agnostic and designed for immediate deployment in clinical settings.
• Cost Reduction: Minimizing repeat procedures and optimizing resource utilization in healthcare systems.
• Scalability: Designed to serve both high-volume academic centers and smaller community hospitals with limited EBUS expertise.

NodeAI is more than an AI tool; it’s a paradigm shift in lung cancer staging. By empowering clinicians with real-time AI-driven insights, we aim to transform lung cancer care, reduce diagnostic uncertainties, and ultimately improve survival rates. Our technology is designed to bridge the gap between expertise and accessibility, ensuring every patient receives the highest standard of care, regardless of their geographical location or the experience of their healthcare provider.

We invite healthcare providers, investors, and strategic partners to join us in our mission to revolutionize the EBUS procedure in lung cancer staging. Together, we can make early and accurate staging accessible to all, improving survival rates and enhancing patient care globally.

Contact us to learn more about how NodeAI is shaping the future of lung cancer staging.